share_log

Independent Non-Executive Director Ting Yuk Wu Sold A Bunch Of Shares In China Resources Medical Holdings

Independent Non-Executive Director Ting Yuk Wu Sold A Bunch Of Shares In China Resources Medical Holdings

獨立非執行董事吳廷玉出售了華潤醫療控股的大量股份
Simply Wall St ·  05/21 19:24

Anyone interested in China Resources Medical Holdings Company Limited (HKG:1515) should probably be aware that the Independent Non-Executive Director, Ting Yuk Wu, recently divested HK$2.6m worth of shares in the company, at an average price of HK$4.41 each. Equally important, that sale actually reduced their holding by a full 100% which hardly makes us feel bullish about the stock.

對於中國資源醫藥控股有限公司(HKG: 1515)感興趣的人,應該注意到獨立非執行董事胡定玉最近以平均每股4.41港元的價格剝離了價值260萬港元的公司股票。同樣重要的是,股東持股比例減少了整整100%,這幾乎讓我們對該股感到看跌。

China Resources Medical Holdings Insider Transactions Over The Last Year

過去一年中中國資源醫藥控股內部交易情況

Notably, that recent sale by Ting Yuk Wu is the biggest insider sale of China Resources Medical Holdings shares that we've seen in the last year. So we know that an insider sold shares at around the present share price of HK$4.27. While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.

值得注意的是,胡定玉最近的這筆交易是我們在過去一年中看到的中國資源醫藥控股股票最大的內部交易。所以我們知道,一位內部人士在大約現有每股4.27港元的價格出售了股票。儘管內部人士的賣出是一個負面因素,但對我們而言,如果股票以更低的價格出售,那就更加負面。考慮到交易是以當前價格進行的,這讓我們有些謹慎,但這並不是一個主要的問題。

Ting Yuk Wu sold a total of 1.00m shares over the year at an average price of CN¥4.38. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

胡定玉在過去的一年中,以平均每股4.38元的價格出售了總計1百萬股。您可以在下方的圖表中看到公司和個人在過去一年中的內部交易情況。如果您點擊圖表,可以看到所有的單個交易情況,包括股價、個人和日期!

insider-trading-volume
SEHK:1515 Insider Trading Volume May 21st 2024
SEHK: 1515內部交易成交量於2024年5月21日

If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.

如果您和我一樣,您就不會錯過這個免費的小盤股票列表,這些股票不僅被內部人士購買,而且估值也很有吸引力。

Insider Ownership Of China Resources Medical Holdings

中國資源醫藥控股股權內部持有情況

For a common shareholder, it is worth checking how many shares are held by company insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. From looking at our data, insiders own HK$9.6m worth of China Resources Medical Holdings stock, about 0.2% of the company. But they may have an indirect interest through a corporate structure that we haven't picked up on. We prefer to see high levels of insider ownership.

對於普通股東而言,了解公司內部人士持有的股份數量很重要。高比例的內部人士持股往往使公司領導更加關注股東利益。根據我們的數據,內部人士持有約960萬港元的中國資源醫藥控股股票,相當於公司的0.2%。但是,他們可能通過我們尚未發現的公司結構間接持有利益。我們更喜歡看到高水平的內部人員持有股份。

What Might The Insider Transactions At China Resources Medical Holdings Tell Us?

中國資源醫藥控股的內部交易對我們有何提示?

An insider sold stock recently, but they haven't been buying. And there weren't any purchases to give us comfort, over the last year. Insiders own relatively few shares in the company, and when you consider the sales, we're not particularly excited about the stock. So we're not rushing to buy, to say the least. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing China Resources Medical Holdings. To assist with this, we've discovered 1 warning sign that you should run your eye over to get a better picture of China Resources Medical Holdings.

一名內部人士最近拋售了股票,但他們並沒有購買。在過去一年中,也沒有任何購買行爲爲我們帶來信心。內部人士持股相對較少,考慮到交易,我們對該股票並不是特別感興趣。此外,了解正在進行的內部交易,識別面臨的風險,對於幫助我們全面了解中國資源醫藥控股公司非常有利。通過此項研究,我們發現了1個警示信號,您可以關注一下以更全面的角度了解中國資源醫藥控股。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果你想查看其他公司——那些具有開多淨資產收益率和低負債的有趣公司的免費清單——那麼不要錯過這個機會。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

對於本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前僅考慮公開市場交易和直接利益的私人處置,但不包括衍生交易或間接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或者,發送電子郵件至editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論